Wednesday, 26 July, 2023 | 12:45pm - 1:45pm
Title: Clinical impact of mass spectrometry* in the management of monoclonal gammopathies
Chair: Prof. Angela Dispenzieri, MD, Mayo Clinic, Rochester, USA
Part 1 - New technologies for M-Protein identification and quantification
Speaker: Jamie Ashby, PhD, Technical development lead, The Binding Site, part of Thermo Fisher Scientific, Birmingham, UK
Part 2 - Improving monoclonal gammopathies management: using mass spectrometry assays in blood sample?
Speaker: Katie Thoren, PhD, Associate Professor, Department of Pathology and Laboratory Medicine, University of Miami
Learning Objectives:
- Review the current practices of monoclonal gammopathy (MG) management, including the challenges and opportunities
- Learn about blood measurement for M-Proteins, and their sensitivity and specificity
- Hear from a user's experience of our future Mass Spectrometry*, in clinical practice
- Understand how mass spectrometry* could address an unmet clinical need in MGs
*This workshop discusses research on potential applications of mass spectrometry in the field of monoclonal gammopathies. The Binding Site, part of Thermo Fisher Scientific is working in this arena although at this time does not have a regulatory cleared product for sale or commercially available for this purpose in the USA and future commercial availability cannot be guaranteed.
Freelite, Hevylite and Optilite are registered trademarks of The Binding Site Group Ltd (Birmingham, UK) in certain countries.